Research To Practice | Oncology Videos

View Top 200 Chart

Back to Rankings Page

Science
**Research To Practice | Oncology Videos**

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

Latest Episodes:

Ovarian Cancer | Consensus or Controversy? Current and Future Management of Ovarian Cancer Nov 30, 2022

Show notes

Featuring perspectives from Drs Ursula Matulonis and Debra Richardson, including the following topics:

PROLOGUE: Antibody-Drug Conjugates Across Oncology (0:00)
Antibody-Drug Conjugates in Ovarian Cancer: Mirvetuximab Soravtansine (10:03)
Antibody-Drug Conjugates in Ovarian Cancer: Upifitamab Rilsodotin (29:09)
Tumor Treating Fields (41:35)
PARP Inhibitor Update (47:29)

CME information and select publications

Renal Cell Carcinoma | Oncology Today with Dr Neil Love: Management of Renal Cell Carcinoma (Companion Faculty Lecture) Nov 29, 2022

Show notes

Featuring a slide presentation and related discussion from Dr Toni Choueiri, including the following topics:

Evolution in the management of renal cell carcinoma (RCC) (0:00)
Adjuvant therapy for intermediate- or high-risk RCC (1:52)
Front-line therapy for patients with metastatic RCC (8:39)
New agents for the treatment of relapsed or refractory RCC (16:24)
Mechanism of action and efficacy of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (19:56)

CME information and select publications

Renal Cell Carcinoma | Oncology Today with Dr Neil Love: Management of Renal Cell Carcinoma Nov 29, 2022

Show notes

Featuring an interview with Dr Toni Choueiri, including the following topics:

Case: A woman in her early 70s with a large kidney tumor and multiple pulmonary nodules (0:00)
Case: A woman in her early 60s diagnosed with metastatic clear cell renal cell carcinoma (RCC) (12:52)
Approach to adjuvant treatment for RCC (16:14)
Examining differences between PD-1 and PD-L1 inhibitors (20:09)
Management of non-clear cell RCC (24:10)
Challenges in identifying patients with RCC who are more likely to benefit from immune checkpoint inhibitors (28:22)
Mechanisms of action of HIF2-alpha inhibitors for von Hippel-Lindau-associated RCC (30:31)
Future directions in the care of patients with RCC (36:24)

CME information and select publications

Non-Small Cell Lung Cancer | Stephen V Liu, MD Nov 28, 2022

Show notes

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 2: Anti-PD-1 and PD-L1 Monotherapy for NSCLC — Dr Stephen Liu

CME information and select publications

Non-Small Cell Lung Cancer | John V Heymach, MD, PhD Nov 28, 2022

Show notes

Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer — Faculty Presentation 1: Current Treatment Landscape for Non-Small Cell Lung Cancer (NSCLC) — Dr John Heymach

CME information and select publications

Non-Small Cell Lung Cancer | Current Paradigm and Future Directions for Immunotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer Nov 28, 2022

Show notes

Featuring perspectives from Drs John Heymach and Stephen Liu, including the following topics:

Introduction (0:00)
Current Immunotherapy-Based Strategies for Non-Small Cell Lung Cancer (NSCLC) (9:29)
Future Directions in the Management of NSCLC (37:09)

CME information and select publications

Breast Cancer | Meet The Professor: Optimizing the Management of HER2-Positive Breast Cancer — Part 3 Nov 22, 2022

Show notes

Featuring perspectives from Dr Lisa Carey, including the following topics:

Introduction: Journal Club with Lisa A Carey, MD, ScM (0:00)
Case: A woman in her late 70s presents with triple-positive breast cancer and a suspicious mass in the liver — Zanetta S Lamar, MD (8:51)
Case: A woman in her mid 40s with ER/PR-negative, HER2-positive metastatic breast cancer with a complete response to paclitaxel/trastuzumab/pertuzumab develops multiple brain metastases 3 months later — Niyati A Nathwani, MD (19:01)
Case: A woman in her mid 30s with triple-positive breast cancer develops brain metastases 5 years after primary neoadjuvant treatment — Rahul Gosain, MD (22:23)
Case: A woman in her mid 40s with ER/PR-positive, HER2-low (IHC 1+) metastatic breast cancer experiences progressive disease after abemaciclib/ovarian function suppression and an aromatase inhibitor — Laila Agrawal, MD (28:22)
Case: A woman in her early 60s with ER/PR-positive, HER2-negative localized breast cancer develops triple-positive metastatic breast cancer — Mamta Choksi, MD (41:16)
Case: A woman in her early 50s with 1.2-cm triple-positive breast cancer who underwent mastectomy (surgical specimen HER2-negative) and adjuvant paclitaxel/trastuzumab now presents with HER2-negative localized recurrence — Namrata I Peswani, MD (43:37)
Faculty Survey (47:53)
Ongoing Trials; Reported Data; Review Articles (55:01)

CME information and select publications

Hepatocellular Carcinoma | Oncology Today with Dr Neil Love: Management of Hepatocellular Carcinoma (Companion Faculty Lecture) Nov 21, 2022

Show notes

Featuring a slide presentation and related discussion from Professor Arndt Vogel, including the following topics:

Advances in first-line treatment for patients with advanced hepatocellular carcinoma (HCC) (0:00)
Outcomes of Phase III clinical trials evaluating single-agent immunotherapy as initial treatment for advanced HCC (4:19)
Immune checkpoint inhibitors as second-line treatment for recurrent HCC (6:03)
Combination therapy as initial treatment for advanced HCC (8:05)
Sequencing therapies for advanced HCC (13:20)
Future directions in caring for patients with advanced HCC (22:43)

CME information and select publications

Hepatocellular Carcinoma | Oncology Today with Dr Neil Love: Management of Hepatocellular Carcinoma Nov 21, 2022

Show notes

Featuring an interview with Professor Arndt Vogel, including the following topics:

Case: A man in his early 40s with hepatitis B virus infection and hepatocellular carcinoma (HCC) with Child-Pugh C, ALBI 3 cirrhosis (0:00)
Case: A man in his late 60s with metastatic HCC with Child-Pugh A, ALBI 2 cirrhosis (7:54)
Case: A man in his early 70s with rheumatoid arthritis diagnosed with Barcelona Clinic Liver Cancer Stage 2 HCC (10:54)
The etiology of HCC and response to immunotherapy (13:20)
Evaluating recent first-line Phase III combination trials for unresectable HCC (19:57)
Managing treatment-emergent adverse events with combination therapies for advanced HCC (25:47)
Potential long-term benefits of immunotherapy-based treatments (29:33)
Impact of recent changes in HCC treatment algorithms on the use of local therapy (31:46)
Use of neoadjuvant therapy to convert unresectable HCC to resectable disease (37:00)
Using tyrosine kinase inhibitors for patients with HCC and comorbidities (44:22)

CME information and select publications

Acute Myeloid Leukemia | Oncology Today with Dr Neil Love: Novel Agents and Strategies in AML Nov 17, 2022

Show notes

Featuring an interview with Dr Eytan Stein, including the following topics:

Practical considerations for using venetoclax/HMA (hypomethylating agent) combinations in the management of acute myeloid leukemia (AML) (0:00)
Approach to transplant for older patients with AML (10:33)
Potential availability of magrolimab and sabatolimab in clinical practice (13:04)
ASH 2022 preview: Investigational therapies excluding transplantation and cellular immunotherapies (17:33)
Activity, tolerability and future directions with FLT3 and IDH inhibitors in AML (22:29)

CME information and select publications